Hemophilia Research Today is a free monthly online journal that collates and summarizes the latest research about Hemophilia, including details on genetics, causes, symptoms, blood transfusion.

The intraoperative use of recombinant FVIIa in child with hemophilia A with antibodies.

Simic D, Milojevic I

Intensive Care Unit, University Children's Hospital, Belgrade, Serbia. dussin@eunet.co.yu

Patients with hemophilia A that developed inhibitors to FVIII represent a problem for bleeding control especially during surgical procedures. We report the use of bolus injections of rFVIIa during one intervention that included synoviectomy on the right knee, cholecystectomy and appendicectomy in a child with high titer of inhibitors to FVIII. rFVIIa was administered at the start (120 microg x kg(-1)) and then every 2 h (90 microg x kg(-1)) during the procedure. epsilon-aminocapronic acid was also administered as an antifibrinolytic every 3 h. We monitored aPTT (activated partial thromboplastin time) and PT (prothrombin time) and they were within reference values. Surgery lasted 7 h without significant hemorrhage. Postoperatively the dose of rFVIIa was slowly reduced and after ten days the patient was discharged home in good condition. In our case rFVIIa helped a child with hemophilia A with antibodies to undergo major surgery but each case should be treated individually and the cost of rFVIIa has also to be taken into account.

Published 28 June 2007 in Paediatr Anaesth, 17(8): 789-92.
Full-text of this article is available online (may require subscription).

© 2005-2008 Hemophilia Research Today. All Rights Reserved.